Company News: Molecular Health and U.S. Food and Drug Administration (FDA) Extend Software Collaboration to Drug Safety Prediction
Molecular Health, Inc (MH), a company marketing computational biomedicine tools to support healthcare decisions with clinical and molecular data, and the FDA’s Center for Drug Evaluation and Research (CDER) have extended for an additional 5 years, their research collaboration to jointly address one of the biggest challenges in drug development: the prediction of drug safety.
– Preparing for expected U.S. FDA clearance decision on Unyvero System and Unyvero LRT Application
– Second U.S. FDA trial initiated for Unyvero IJI Application
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the first nine months ended September 30, 2017, and provided details on its outlook for the coming months.
Check out the latest video by our client Curetis for the ongoing World Antibiotic Awareness Week: